Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06365840 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06365840 · ClinicalTrials.gov record · last posted 2026-04-17

A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor

Study acronym: TMB-H
StatusRecruiting
PhasePhase 2
Started2025-01-13
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The goal of this clinical trial is to determine the efficacy of IMC-001 in metastatic or locally advanced TMB-H solid tumor patients.

Amendment record 2 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 2 times since 2024-04-10; most recent amendment 2026-04-16. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-06-16
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT06365840
Lead Sponsor ImmuneOncia Therapeutics Inc.
Conditions TMB-H, Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
Enrollment 30 participants
Start Date 2025-01-13
Primary Completion 2027-06-30 (estimated)
Study Completion 2029-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-17